Back to search

Duquesne

DESIGN, SYNTHESIS, AND CHARACTERIZATION OF MULTI-TARGETING PYRROLOPYRIMIDINE ANTIFOLATES AS POTENTIAL SINGLE AGENT CHEMOTHERAPEUTIC ENTITIES

Abstract

dc:description.abstract

In cancer chemotherapy, the currently marketed antifolates have two major disadvantages: dose-limiting toxicities to normal tissues and susceptibility to drug resistance. These are due to their major transport by the ubiquitously expressed transporter and mutagenesis in enzymes present in cancer cells. This thesis describes an introduction, background, and research progress in antimetabolites-antifolates designed to multi-target (a) one-carbon metabolism and de novo nucleotide synthesis pathway and (b) target overexpressed transporter in cancer cells for selective tumor-targeting. Cancer cells transport folate through three transporters: ubiquitously expressed reduced folate carrier (RFC), limitedly expressed proton-coupled folate transporter (PCFT), and folate receptors (FRs). The research strategies that have developed drugs that target PCFT and/or FRs transporter, which could only minimize the dose-limiting toxicity issue through specificity for cancer cells. To address the mutagenesis/ drug resistance issue, one must target multiple enzymes such that the cancer cells can not simultaneously mutate multiple targets. Moreover, in cancer cells, one-carbon metabolism enzymes supported by folate metabolism are known to be upregulated and serve to activate multiple biosynthetic processes, including de novo purine and thymidine synthesis and homocysteine remethylation, required for their proliferation and survival. Thus, the next valid step is to design and synthesize compounds that can address mutagenesis/drug resistance and toxicity issues by targeting multiple one-carbon metabolism enzymes along with transport specificity in cancer cells. Pemetrexed (PMX), initially named as a multitargeted antifol (MTA) and now with the trade name Alimta, was approved for several cancers, including non-small-cell lung cancer and mesothelioma, and has three disadvantages: (1) Its major transport is by the ubiquitously expressed RFC; (2) It is dependent on its polyglutamylation for potency, and (3) It has developed resistance due to mutagenesis in folypolygultamate synthase (FPGS), thymidylate synthase (TYMS) and dihydrofolate reductase (DHFR). The work in this thesis involves the design and the development of a part of a pipeline of pyrrolo-pyrimidine antifolates that are superior to PMX as they circumvent the disadvantages of PMX.

Degree

thesis:*
Name thesis:degree_name
MS
Level thesis:degree_level
One-year Embargo
Discipline thesis:degree_discipline
Medicinal Chemistry

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Magdum, Tejashree
Contributors dc:contributor
  • Aleem Gangjee
  • Patrick T. Flaherty
  • Marc Harrold

Subjects

dc:subject × 6

Rights

Language dc:language
English

Identifiers

dc:identifier.*
Repository record dc:identifier
https://dsc.duq.edu/etd/2411

Chain of custody

source
Harvested from
Duquesne
Base URL
dsc.duq.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Magdum, Tejashree. DESIGN, SYNTHESIS, AND CHARACTERIZATION OF MULTI-TARGETING PYRROLOPYRIMIDINE ANTIFOLATES AS POTENTIAL SINGLE AGENT CHEMOTHERAPEUTIC ENTITIES. One-year Embargo thesis, https://dsc.duq.edu/etd/2411